• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    51.75 -0.65 (-1.24%)
    Streaming Delayed Price Updated: 10:49 AM EST, Dec 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,063,678
    Open 51.56
    Bid (Size) 51.74 (600)
    Ask (Size) 51.75 (400)
    Prev. Close 52.40
    Today's Range 51.45 - 51.99
    52wk Range 43.08 - 93.80
    Shares Outstanding N/A
    Dividend Yield 4.25%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
    As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of... 
    Via PredictStreet
    Topics Earnings Economy Intellectual Property
    News headline image
    Market Breather: Benchmarks Pause Record-Breaking Year as Volatility Signals Year-End Reset
    As the final trading days of 2025 approach, the relentless momentum that propelled major U.S. indices to historic heights has entered a period of measured consolidation. After a year defined by the... 
    Via MarketMinute
    Topics Artificial Intelligence Bonds Economy

    Performance

    YTD
    -40.9%
    -40.9%
    1 Month
    +4.9%
    +4.9%
    3 Month
    -6.8%
    -6.8%
    6 Month
    -25.0%
    -25.0%
    1 Year
    -39.6%
    -39.6%

    More News

    Read More
    News headline image
    This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗
    Via The Motley Fool
    News headline image
    Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗
    Via The Motley Fool
    News headline image
    3 Drug Stocks to Buy at a Discount ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗
    Via The Motley Fool
    News headline image
    Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗
    Via MarketBeat
    News headline image
    This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
    Via Stocktwits
    News headline image
    Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗
    Via The Motley Fool
    News headline image
    Betting on the 'Santa Squeeze': Unusual Options Activity Surges as 2025 Draws to a Close
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗
    Via The Motley Fool
    News headline image
    Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
    Via MarketMinute
    Topics Economy Intellectual Property
    News headline image
    The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
    Via PredictStreet
    Topics Economy Intellectual Property World Trade
    News headline image
    The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
    Via PredictStreet
    Topics Economy Government Intellectual Property
    News headline image
    The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
    Via PredictStreet
    Topics Economy
    News headline image
    Novo Nordisk (NVO) Research: The Oral Wegovy Pivot and the 2026 Outlook
    Via PredictStreet
    Topics Economy Intellectual Property
    News headline image
    Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗
    Via Stocktwits
    News headline image
    Novo Nordisk A/S-Spons ADR (NYSE:NVO): A Prime Candidate for Steady Dividend Income ↗
    Via Chartmill
    News headline image
    Stock Market Today, Dec. 23: U.S. Stocks Hold Near Records on Narrow Tech-Led Gains ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Why Novo Nordisk Stock Popped Today ↗
    Via The Motley Fool
    News headline image
    Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market
    Via MarketMinute
    News headline image
    Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
    Via MarketMinute
    Topics Economy
    News headline image
    Which stocks are most active on Tuesday? ↗
    Via Chartmill

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 51.75
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 12/29/25 10:49 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.